Note that some links may require subscriptions.
To ease a looming shortage of the hypertension drug losartan, the FDA is temporarily raising the limit on allowable contamination with NMBA (a possible carcinogen) by 10-fold, to 9.82 parts per million, which agency scientists say is safe enough.
The FDA approved solriamfetol (Sunosi) as a treatment for daytime sleepiness in narcolepsy or obstructive sleep apnea, Jazz Pharmaceuticals announced.
At least three patients in Vancouver died after coatings peeled off certain endovascular devices, leading to hydrophilic polymer embolism — a problem known since 2015 — but Health Canada has still done nothing. (Vancouver Sun)
Oh no, not kale! Sorry, but yes — it’s on the Environmental Working Group’s “Dirty Dozen” list of products laden with pesticide residues, along with at least 10 other things you thought were healthy.
A federal judge temporarily blocked a Kentucky law that would impose more restrictions on abortion. (ABC News)
And that state’s governor said he purposefully exposed his children to chickenpox in place of vaccination. (AP)
Ebola is still spreading in the eastern part of the Democratic Republic of Congo. (Reuters)
A Reuters report suggested that China’s African swine fever epidemic on hog farms is worse than officials say.
Among adults prescribed medication in the past 12 months, almost 40% asked their doctor for a cheaper medication, more than 33% didn’t take their medication as prescribed, and almost 14% used alternative therapies. (FierceHealthcare)
Is Instagram a viable part of the medical landscape? Medical student Anum Iqbal thinks so. (KevinMD)
Roman, the men’s health start-up specializing in erectile dysfunction, is expanding its product line to include menopausal women. (CNBC)
Screening for pulmonary embolism doesn’t have to include CT pulmonary angiography for pregnant women: a pregnancy-adapted version of the YEARS diagnostic algorithm can safely rule it out across all trimesters of pregnancy, researchers reported in the New England Journal of Medicine.
Novo Nordisk thinks it has enough data on its oral peptide drug semaglutide for type 2 diabetes to win U.S. approval. (Reuters)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]thinc.com